Amid ongoing debate over the role the pharmaceutical industry plays in shaping health policy, a new analysis finds that patient groups funded by drug makers generally support corporate interests, few groups have policies governing industry backing, and transparency is often lacking.

A systematic review of 26 studies that examined patient advocacy groups found industry funding ranged from 20% to 83% of these organizations. Of those that received corporate backing, only 27% disclosed this information on their web sites. In addition, anywhere from 2% to 64% of the groups had policies concerning corporate sponsorship, according to the analysis, which was published in BMJ.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy